Journal of pediatric ophthalmology and strabismus · 2024
Variability in the Evaluation and Treatment of Healthy Neonates With Uncomplicated Conjunctivitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nelson Camden, Deshler Bailee J, Bernstein Brittany, Aronoff Stephen
Аннотация
PURPOSE: To explore the current state of diagnosis and management of neonatal conjunctivitis.
METHODS: Cosmos, an EHR-based, de-identified data set including more than 200 million patients, was used for this study. Neonates born between January 1, 2016 and December 31, 2022, discharged from the hospital by day 3 of life, and with an ambulatory visit within the first 4 weeks of life associated with a new diagnosis of neonatal conjunctivitis (SNOMED) or conjunctivitis (ICD-10 H10.*) were included. Cosmos slicer/dicer software was used to extract demographic, diagnostic, etiologic, and therapeutic data.
RESULTS: A total of 1,870 of 7,325,276 (0.0255%) neonates with a hospital stay of 3 days or less met criteria for inclusion: 96.5% were from the United States, 16.2% were admitted to the hospital, and bacterial cultures were obtained from 21.3%. Congenital lacrimal duct stenosis was causative in 2.7% of patients. Important infectious agents included staphylococcal, streptococcal, or enterococcal species (2.5%), Neisseria gonorrhoeae (1.6%), and Chlamydia trachomatis (0.6%). No herpesviral or Pseudomonas infections were identified. Antimicrobial agents were prescribed to 93.7% of patients and given ophthalmically (79.5%), orally (11.4%), and parenterally (7.7%).
CONCLUSIONS: The evaluation and management of neonatal conjunctivitis within United States ambulatory settings are highly variable. Diagnostic studies are underused, resulting in limited etiologic data and a lack of susceptibility-guided treatment. [J Pediatr Ophthalmol Strabismus. 2025;62(2):143-149.].
METHODS: Cosmos, an EHR-based, de-identified data set including more than 200 million patients, was used for this study. Neonates born between January 1, 2016 and December 31, 2022, discharged from the hospital by day 3 of life, and with an ambulatory visit within the first 4 weeks of life associated with a new diagnosis of neonatal conjunctivitis (SNOMED) or conjunctivitis (ICD-10 H10.*) were included. Cosmos slicer/dicer software was used to extract demographic, diagnostic, etiologic, and therapeutic data.
RESULTS: A total of 1,870 of 7,325,276 (0.0255%) neonates with a hospital stay of 3 days or less met criteria for inclusion: 96.5% were from the United States, 16.2% were admitted to the hospital, and bacterial cultures were obtained from 21.3%. Congenital lacrimal duct stenosis was causative in 2.7% of patients. Important infectious agents included staphylococcal, streptococcal, or enterococcal species (2.5%), Neisseria gonorrhoeae (1.6%), and Chlamydia trachomatis (0.6%). No herpesviral or Pseudomonas infections were identified. Antimicrobial agents were prescribed to 93.7% of patients and given ophthalmically (79.5%), orally (11.4%), and parenterally (7.7%).
CONCLUSIONS: The evaluation and management of neonatal conjunctivitis within United States ambulatory settings are highly variable. Diagnostic studies are underused, resulting in limited etiologic data and a lack of susceptibility-guided treatment. [J Pediatr Ophthalmol Strabismus. 2025;62(2):143-149.].